151 related articles for article (PubMed ID: 33114048)
1. Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI.
Taghizadeh H; Unseld M; Spalt M; Mader RM; Müllauer L; Fuereder T; Raderer M; Sibilia M; Hoda MA; Aust S; Polterauer S; Lamm W; Bartsch R; Preusser M; A KW; Prager GW
J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33114048
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers.
Taghizadeh H; Mader RM; Müllauer L; Fuereder T; Kautzky-Willer A; Prager GW
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33203166
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.
Kieler M; Unseld M; Bianconi D; Waneck F; Mader R; Wrba F; Fuereder T; Marosi C; Raderer M; Staber P; Berger W; Sibilia M; Polterauer S; Müllauer L; Preusser M; Zielinski CC; Prager GW
ESMO Open; 2019; 4(4):e000538. PubMed ID: 31423337
[TBL] [Abstract][Full Text] [Related]
4. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
[TBL] [Abstract][Full Text] [Related]
5. Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.
Kieler M; Müllauer L; Koperek O; Bianconi D; Unseld M; Raderer M; Prager GW
Oncology; 2018; 94(5):306-310. PubMed ID: 29444511
[TBL] [Abstract][Full Text] [Related]
6. Precision Medicine for the Management of Therapy Refractory Colorectal Cancer.
Taghizadeh H; Mader RM; Müllauer L; Erhart F; Kautzky-Willer A; Prager GW
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33322358
[TBL] [Abstract][Full Text] [Related]
7. Applied Precision Cancer Medicine in Neuro-Oncology.
Taghizadeh H; Müllauer L; Furtner J; Hainfellner JA; Marosi C; Preusser M; Prager GW
Sci Rep; 2019 Dec; 9(1):20139. PubMed ID: 31882734
[TBL] [Abstract][Full Text] [Related]
8. Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.
Taghizadeh H; Maj-Hes A; Prager GW; Müllauer L; Mader RM
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454843
[TBL] [Abstract][Full Text] [Related]
9. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.
Taghizadeh H; Müllauer L; Mader RM; Schindl M; Prager GW
Ther Adv Med Oncol; 2020; 12():1758835920938611. PubMed ID: 32699558
[TBL] [Abstract][Full Text] [Related]
10. Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H; Müllauer L; Mader RM; Füreder T; Prager GW
Wien Klin Wochenschr; 2021 Jan; 133(1-2):32-40. PubMed ID: 33296026
[TBL] [Abstract][Full Text] [Related]
11. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
13. Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience.
Cordova-Delgado M; Pinto MP; Regonesi C; Cereceda L; Reyes JM; Itriago L; Majlis A; Rodríguez P; Fassler A; Mahave M; León ME; Gallardo J; Rodríguez Z MP; Berkovits A; Manque P; Ríos JA; Garcia-Bloj B; Garrido M
J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207683
[TBL] [Abstract][Full Text] [Related]
14. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
15. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
[TBL] [Abstract][Full Text] [Related]
16. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
17. Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.
Billon E; Gravis G; Guille A; Carbuccia N; Adelaide J; Garnier S; Finetti P; Denicolaï E; Sfumato P; Brunelle S; Thomassin-Piana J; Pignot G; Walz J; Chabannon C; Pakradouni J; Sabatier R; Vicier C; Popovici C; Mamessier E; Gonçalves A; Birnbaum D; Chaffanet M; Bertucci F
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565404
[TBL] [Abstract][Full Text] [Related]
18. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine for gastrointestinal cancer: Recent progress and future perspective.
Matsuoka T; Yashiro M
World J Gastrointest Oncol; 2020 Jan; 12(1):1-20. PubMed ID: 31966910
[TBL] [Abstract][Full Text] [Related]
20. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
